Syntara on advancing first-in-class Myelofibrosis therapy with multiple pipeline opportunities
Welcome to the latest HotCopper Capital Compass, where we’ve this week spoken to Syntara Ltd (ASX:SNT) chief Gary Phillips for a high-level overview on the biotech company’s objectives in treating blood cancers and fibrosis, what underpins its value proposition, an...
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
| Tag | Subject | ||||||
|---|---|---|---|---|---|---|---|
| LT9 | Ann: Monthly Report - January 2026 | 18/02/26 | 0 | 114 | |||
|
|||||||
| LT9 | Ann: Monthly Report - December 2025 | 15/01/26 | 0 | 101 | |||
|
|||||||
| LT9 | Ann: Monthly Report - November 2025 | 17/12/25 | 0 | 74 | |||
|
|||||||
| LT9 | Ann: Monthly Report - October 2025 | 17/11/25 | 0 | 125 | |||
|
|||||||
| LT9 | Ann: Monthly Report - September 2025 | 15/10/25 | 0 | 73 | |||
|
|||||||
| LT9 | Ann: Capital Markets Trust Annual Report FY25 | 13/10/25 | 0 | 81 | |||
|
|||||||
| LT9 | Ann: Monthly Report - August 2025 | 12/09/25 | 0 | 134 | |||
|
|||||||
| LT9 | Ann: Monthly Report - July 2025 | 18/08/25 | 0 | 165 | |||
|
|||||||
See All Discussions
Timeline
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
| View More | |||||
ASX News